Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat Monotherapy and with Bortezomib/Dexamethasone in RRMM
NCT01323751Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ricolinostat in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jul 2011; status: completed.
02
Drugs
ricolinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01323751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01323751.